Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells

Guoyue Lu, Yahui Liu, Bai Ji, Feng Wei, Chunhai Hao, Guangyi Wang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently under clinical development as a cancer therapeutic because it can induce apoptosis selectively in cancer cells. The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL. In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. The study suggests a framework for TRAIL-based combination treatment of HCC.

Original languageEnglish (US)
Pages (from-to)629-634
Number of pages6
JournalCancer Investigation
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Celecoxib
Hepatocellular Carcinoma
Apoptosis
Caspase 1
Camptothecin
Neoplasms
Caspase 8
Caspase 3
Down-Regulation
Tumor Necrosis Factor-alpha
Ligands
Cell Line
Therapeutics

Keywords

  • C-FLIP
  • Caspase-8
  • Celecoxib
  • Hepatocellular Carcinoma
  • TRAIL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. / Lu, Guoyue; Liu, Yahui; Ji, Bai; Wei, Feng; Hao, Chunhai; Wang, Guangyi.

In: Cancer Investigation, Vol. 28, No. 6, 01.06.2010, p. 629-634.

Research output: Contribution to journalArticle

Lu, Guoyue ; Liu, Yahui ; Ji, Bai ; Wei, Feng ; Hao, Chunhai ; Wang, Guangyi. / Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. In: Cancer Investigation. 2010 ; Vol. 28, No. 6. pp. 629-634.
@article{2c37457da97842a9b22c905ce1871f94,
title = "Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells",
abstract = "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently under clinical development as a cancer therapeutic because it can induce apoptosis selectively in cancer cells. The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL. In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. The study suggests a framework for TRAIL-based combination treatment of HCC.",
keywords = "C-FLIP, Caspase-8, Celecoxib, Hepatocellular Carcinoma, TRAIL",
author = "Guoyue Lu and Yahui Liu and Bai Ji and Feng Wei and Chunhai Hao and Guangyi Wang",
year = "2010",
month = "6",
day = "1",
doi = "10.3109/07357900903095631",
language = "English (US)",
volume = "28",
pages = "629--634",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells

AU - Lu, Guoyue

AU - Liu, Yahui

AU - Ji, Bai

AU - Wei, Feng

AU - Hao, Chunhai

AU - Wang, Guangyi

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently under clinical development as a cancer therapeutic because it can induce apoptosis selectively in cancer cells. The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL. In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. The study suggests a framework for TRAIL-based combination treatment of HCC.

AB - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently under clinical development as a cancer therapeutic because it can induce apoptosis selectively in cancer cells. The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL. In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. The study suggests a framework for TRAIL-based combination treatment of HCC.

KW - C-FLIP

KW - Caspase-8

KW - Celecoxib

KW - Hepatocellular Carcinoma

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=77953179539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953179539&partnerID=8YFLogxK

U2 - 10.3109/07357900903095631

DO - 10.3109/07357900903095631

M3 - Article

C2 - 20394499

AN - SCOPUS:77953179539

VL - 28

SP - 629

EP - 634

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 6

ER -